Literature DB >> 31075309

Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history.

Jonathan Corren1, Mario Castro2, Linda B Ford3, Jonathan A Bernstein4, Shyamalie Jayawardena5, Jaman Maroni6, Paul Rowe5, Nikhil Amin6, Gianluca Pirozzi5, Neil M H Graham6, Asif Khan7, Laurent Eckert7, Ariel Teper5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31075309     DOI： 10.1016/j.anai.2019.04.028

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN： 1081-1206            Impact factor:   6.347


× No keyword cloud information.
  3 in total

Review 1.  Dupilumab: A Review in Moderate to Severe Asthma.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2019-11       Impact factor: 9.546

Review 2.  Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma.

Authors:  Andrew Gallagher; Michaela Edwards; Parameswaran Nair; Stewart Drew; Aashish Vyas; Rashmi Sharma; Paul A Marsden; Ran Wang; David Jw Evans
Journal:  Cochrane Database Syst Rev       Date:  2021-10-19

Review 3.  Severe Asthma and Biological Therapy: When, Which, and for Whom.

Authors:  Paola Rogliani; Luigino Calzetta; Maria Gabriella Matera; Rossella Laitano; Beatrice Ludovica Ritondo; Nicola A Hanania; Mario Cazzola
Journal:  Pulm Ther       Date:  2019-12-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.